Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not limited to leukemias and solid tumors, in mammals, especially humans.
Type:
Application
Filed:
September 17, 2014
Publication date:
March 26, 2015
Applicants:
SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Type:
Grant
Filed:
July 19, 2013
Date of Patent:
March 10, 2015
Assignees:
Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
Inventors:
Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Type:
Grant
Filed:
July 19, 2013
Date of Patent:
March 3, 2015
Assignees:
Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
Inventors:
Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Type:
Application
Filed:
July 19, 2013
Publication date:
February 19, 2015
Applicants:
Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.
Inventors:
Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Type:
Application
Filed:
July 19, 2013
Publication date:
February 5, 2015
Applicants:
Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
Inventors:
Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Type:
Application
Filed:
February 15, 2014
Publication date:
August 21, 2014
Applicants:
SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Abstract: The present invention provides substituted azaindole prodrugs, methods of making said prodrugs, pharmaceutical compositions of said prodrugs and methods of using said prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as cancer.
Type:
Application
Filed:
August 26, 2013
Publication date:
February 27, 2014
Applicants:
Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
Inventors:
Ning Xi, Tingjin Wang, Yin Tang, Mingming Sun, Qian Wang